Analysis of T-cell receptor gene rearrangement in lymph nodes of patients with mycosis fungoides. Prognostic implications.
OBJECTIVE
To determine the prognostic value of analyzing lymph node (LN) DNA from patients with mycosis fungoides for the presence of a monoclonal T-cell population.


METHODS
Inception cohort study.


METHODS
A tertiary care referral center in Seattle, Wash.


METHODS
Fifty-five uniformly staged patients with the diagnosis of mycosis fungoides and who had a lymph node biopsy, 21 with clinically abnormal nodes and 34 with normal nodes.


METHODS
Lymph nodes were evaluated by Southern blot analysis for T-cell receptor beta-chain (TCRB) gene rearrangement and by histopathologic examination for the LN classification using the National Cancer Institute system. Patients were observed clinically for a mean (+/- SD) of 4.7 +/- 3.4 years.


RESULTS
Patients with detectable TCRB gene rearrangement in lymph node DNA had an increased likelihood of a poor clinical outcome and a decreased probability of survival (P < .001 for both) compared with patients with the TCRB germline. Although patients with clinically enlarged nodes were more likely to have the TCRB gene rearranged, those with normal nodes and the TCRB gene rearranged also had a poor clinical outcome and a decreased probability of survival. Similar to those with the TCRB gene rearranged, most patients with advanced histopathologic changes (LN3 and LN4) had a poor prognosis. The presence of a rearranged TCRB gene, however, correctly predicted some patients with intermediate LN scores (LN2) who had a poor clinical outcome.


CONCLUSIONS
Detection of a monoclonal T-cell population, as demonstrated by a rearranged TCRB gene on Southern blot analysis, in LNs of patients with mycosis fungoides is predictive of a poor clinical outcome and a reduced probability of survival. Lymph node TCRB gene analysis provides additional prognostic information for patients with mycosis fungoides with intermediate LN histopathology.
Kern
D E
DE
Department of Medicine, University of Washington School of Medicine, Seattle, USA.
Kidd
P G
PG
Moe
R
R
Hanke
D
D
Olerud
J E
JE
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D015139:Blotting, Southern; D002423:Cause of Death; D015331:Cohort Studies; D016001:Confidence Intervals; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015333:Gene Rearrangement, beta-Chain T-Cell Antigen Receptor / Q000235:genetics*; D006801:Humans; D008198:Lymph Nodes / Q000378:metabolism* / Q000473:pathology; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000235:genetics* / Q000473:pathology; D009367:Neoplasm Staging; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction; D015203:Reproducibility of Results; D012878:Skin Neoplasms / Q000235:genetics* / Q000473:pathology; D015996:Survival Rate; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm